

Uppsala 2018-10-29

## **Patent protecting Temodex and SI053 covering the Eurasian market has been granted**

The institution of Physical and Chemical Problems' (Minsk) patent application, which protects Temodex and SI053 has been granted by the Eurasian Patent Organization (EAPO). The patent approval provides protection for the products on the Eurasia market at least through 2036. The Eurasian patent is a part of a patent family filed in collaboration with Double Bond Pharmaceutical. The international patent application protecting SI053 received a positive Written Opinion during the international phase, and has just entered the national phase in US, EP, Asia, and other countries of interest.

"I am very glad that the first patent from the patent family protecting SI053 has been granted," - comments Igor Lokot, CEO for Double Bond Pharmaceutical. – "With the patent, we have achieved an important interim goal for the commercialization of our front-line product SI-053 for the treatment of brain tumors."

**More about Temodex:** Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared to pass through all the tests and trials required for registration within the EU and globally. The product has a working name SI-053 in DBP pipeline. **Video presentation:** <https://youtu.be/iweOQPq316o>

**More about The institution of Physical and Chemical Problems:** <http://www.fhp.bsu.by/english>

**More about Eurasian Patent Organization (EAPO):** <https://www.eapo.org/en/>

**Eurasian Market covered by EAPO:** Republic of Belarus, Republic of Tajikistan, Russian Federation, Republic of Kazakhstan, Azerbaijan Republic, Kyrgyz Republic, Republic of Armenia

*This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 29 of October 2018.*

---

**Full Company Name:** Double Bond Pharmaceutical International AB (publ)

**Corporate identity:** 556991-6082

**Stock short name:** DBP B

**Share ISIN code:** SE0007185525

For more info, contact

Igor Lokot, CEO

Homepage: <http://www.doublebp.com/>

**E-mail:** [info@doublebp.com](mailto:info@doublebp.com)

Blog: <http://blog.doublebp.com>

Follow us on LinkedIn (<https://www.linkedin.com/company/double-bond-pharmaceutical?trk=co-feed-likes-one>) and Twitter (<https://twitter.com/DoubleBondPharm>)!

---

### **Information on Double Bond Pharmaceutical International AB**

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company's own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.